Be the first person to write a business review for Mediatech, Inc.

The Medical Research Council (MRC) is a not-for-profit UK government-financed organization that promotes and funds medical and other health-related research. Founded in 1913, MRC funding has been responsible for some of the biggest breakthroughs in life sciences, such as the purification of penicillin and the development of magnetic resonance imaging (MRI) technology. The council's funding is distributed to researchers in universities, the National Health System, and MRC research centers. Current research priorities include AIDS, antibiotic resistance, the use of animals in research, chronic fatigue syndrome, the study of cognitive systems, intensive care, multiple sclerosis, and other areas of public health.

MediciNova, Inc. company was founded in 2000 and is headquartered in San Diego, California. MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The company's development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which is in Phase II clinical trial for the treatment of acute exacerbations of asthma; and MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis. The company's other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed second Phase I clinical trial for the treatment of solid tumors; MN-305, which completed a Phase II/III clinical trial for the treatment of generalized anxiety disorder and a Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders.

Medicis Pharmaceutical Corporation was founded in 1987 and is headquartered in Scottsdale, Arizona. Medicis Pharmaceutical Corporation operates as a specialty pharmaceutical company in the United States and Canada. It develops and markets products for the treatment of dermatological, aesthetic, and podiatric conditions. The company's products address various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. Its products include DYNACIN for the treatment of acne and acne-related dermatological conditions; PLEXION, a cleanser product; SOLODYN for the treatment of inflammatory lesions; TRIAZ, a benzoyl peroxide pad for the topical treatment of acne vulgaris; and ZIANA, a gel used on the skin for treatment of acne in patients 12 and older.Medicis Pharmaceutical also offers LOPROX, a shampoo; PERLANE and RESTYLANE for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds; and VANOS, a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. In addition, Medicis Pharmaceutical provides non-dermatological products, including AMMONUL for treating hepatic encephalopathies; and BUPHENYL for the treatment of urea cycle disorder. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has a joint development agreement with IMPAX Laboratories, Inc. to develop of five strategic dermatology product opportunities, including an advanced-form SOLODYN product; a strategic alliance with AAIPharma, Inc. for the development, commercialization, and license of a key dermatologic product, SOLODYN; and a strategic collaboration with Hyperion Therapeutics, Inc. for the research and development of a compound referred to as GT4P for the treatment of urea cycle disorder and hepatic encephalopathies.

Medifacts was founded in 1985 as Core Laboratory Services and has facilities in the US, Germany, and China. Medifacts International, Inc. company specializes in cardiovascular safety data management services, including ECG (electrocardiogram) and ambulatory blood pressure monitoring services, for clients conducting pharmaceutical, biotech, and medical device development trials. It also provides data collection, consulting, training, and telemedicine services. The company has sold its Clinical Research Services division, which offered broader data management services for clinical trials.

MediGene develops drugs that save lives or just make life easier. Spun off from the Munich Gene Center in 1994, MediGene focuses its R&D efforts on therapies that battle various forms of cancer and autoimmune conditions. It also has several drugs on the market, many of them sold through partnerships with other drug firms. The company's Eligard treatment for prostate cancer is sold in Europe by Astellas Pharma, and its Veregen ointment for genital warts is on the US market (Bradley Pharmaceuticals (now part of Nycomed US) sells the drug). In 2008 MediGene won approval from European regulatory authorities for Oracea, a treatment for rosacea; it sold European marketing rights for the drug to Galderma Laboratories.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.